Agennix AG

Agennix AG is a Germany-based biopharmaceutical company. The Company focuses on the development of therapies, which improve the lives of critically ill patients in areas of major unmet medical need. The Company is focused on pharmaceutical companies and biotechnology firms with presence in the area of critical care and/or cancer development and commercialization. The Company’s investigational agents include oral talactoferrin; a topical gel formulation of talactoferrin for treating chronic wounds, and RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer. The Company’s site of operation is in Princeton, New Jersey.

Full List of Officers

Christof Hettich
Chairman of the Supervisory Board
Start date: 2009-11-

Torsten Hombeck
Spokesperson of the Management Board, Chief Financial Officer
Start date: 2009-11-

Frank Young
Vice Chairman of the Supervisory Board
Start date: 2009-11-

Rajesh Malik
Member of the Management Board, Chief Medical Officer
Start date: 2009-11-

Alan Feinsilver
Member of the Supervisory Board

Bernd Seizinger
Member of the Supervisory Board

Friedrich von Bohlen und Halbach
Member of the Supervisory Board
Start date: 2009-11-

James Weaver
Member of the Supervisory Board

Date of incorporation
Country of incorporation DEU
Phone +49 89 90405464
Fax +49 89 90405811
Investor relations contact

+49 7461 90065653

Free float 15702368
Security description Common Stock
Main venue Frankfurt Stock Exchange
Ticker at main venue AGX
Location

Landsbergerstrasse 302
80687 MUNICH

Share price
/
 
Earnings per share
=
0.05
(
 
Share price
x
 
Shares
+
 
Net debt
) /
 
EBIT
=
INF
Price
x
 
Shares
/
 
Net Sales
=
0
(
 
Share price
x
 
Shares
+
 
Net debt
) /
 
Net sales
=
0
Price
x
 
Shares
/
 
Own capital
=
0
Earnings per share
x
 
Shares
/
 
Own capital
=
0.05%
Dividend per share
/
 
Price
=
-17.24%
2011 2010 2009 2008 2007
Income statement
Revenue 0.00 0.15 7.75 12.37
Other Revenue, Total
Total Revenue 0.00 0.15 7.75 12.37
Revenue Change -100% -98% -37.4%
Cost of Revenue, Total
Gross Profit
Selling/General/Admin. Expenses, Total 8.81 9.98 13.14 15.16
EBITDA
EBITDA margin (%)
Research & Development 36.64 29.36 6.72 16.82
Depreciation/Amortization 0.01 0.05 0.17 0.21
Interest Exp.(Inc.),Net-Operating, Total
Unusual Expense (Income) 0.00 0.02 3.38 2.38
Other Operating Expenses, Total -3.23 -2.97 -1.33 0.61
Total Operating Expense 42.23 36.45 22.08 35.18
Operating Income -42.23 -36.30 -14.34 -22.80
EBIT margin (%)
Interest Inc.(Exp.),Net-Non-Op., Total
Gain (Loss) on Sale of Assets
Other, Net 0.00 0.00 0.00 -0.02
Net Income Before Taxes -42.63 -36.49 -13.08 -21.28
Provision for Income Taxes -0.80 -9.49 -1.14 0.00
Net Income After Taxes -41.83 -27.00 -11.94 -21.28
Minority Interest
Equity In Affiliates
U.S. GAAP Adjustment
Net Income Before Extra. Items -41.83 -27.00 -11.94 -21.28
Total Extraordinary Items
Net Income -41.83 -27.00 -11.94 -21.28
Total Adjustments to Net Income
Income Available to Com Excl ExtraOrd -41.83 -27.00 -11.94 -21.28
Income Available to Com Incl ExtraOrd -41.83 -27.00 -11.94 -21.28
Dilution Adjustment 0.00 0.00 0.00 0.00
Diluted Net Income -41.83 -27.00 -11.94 -21.28
Diluted Weighted Average Shares 42.55 25.25 9.14 7.37
Diluted EPS Excluding ExtraOrd Items -0.98 -1.07 -1.31 -2.89
DPS - Common Stock Primary Issue 0.00 0.00 0.00 0.00
Diluted Normalized EPS -0.98 -1.06 -1.04 -2.57
Balance sheet
Cash 23.91 49.02 11.41 31.69
Cash & Equivalents
Short Term Investments 20.02 30.20 0.00 0.14
Cash and Short Term Investments 43.94 79.21 11.41 31.82
Accounts Receivable - Trade, Net 0.00 0.00 0.04 0.01
Total Receivables, Net 2.94 0.33 0.04 0.01
Total Inventory
Prepaid Expenses 2.67 1.42 0.60 0.43
Other Current Assets, Total 0.20 0.01 0.26 2.21
Total Current Assets 49.74 80.98 12.30 34.47
Property/Plant/Equipment, Total - Gross 6.67 5.76 5.09 2.37
Accumulated Depreciation, Total -2.99 -2.29 -1.68 -1.85
Property/Plant/Equipment, Total - Net 3.68 3.46 3.42 0.52
Goodwill, Net
Intangibles, Net 101.96 99.47 91.88 3.58
Long Term Investments
Note Receivable - Long Term
Other Long Term Assets, Total 0.55 2.15 2.04 0.15
Total Assets 155.93 186.06 109.64 38.72
Accounts Payable 3.01 5.02 1.59 1.22
Payable/Accrued
Accrued Expenses 0.24 0.26 5.33 4.75
Notes Payable/Short Term Debt 0.00 15.39 0.00 0.00
Current Port. of LT Debt/Capital Leases 0.03 0.00
Other Current liabilities, Total 4.84 4.73 0.04 0.04
Total Current Liabilities 8.12 25.41 6.97 6.01
Long Term Debt 0.18 0.21 0.21 1.71
Capital Lease Obligations
Total Long Term Debt 0.18 0.21 0.21 1.71
Total Debt 0.21 15.60 0.21 1.71
Deferred Income Tax 6.95 7.63 15.85 0.00
Minority Interest
Other Liabilities, Total 0.00 0.02 0.03 7.38
Total Liabilities 15.25 33.27 23.06 15.10
Redeemable Preferred Stock, Total
Preferred Stock - Non Redeemable, Net
Common Stock, Total 51.27 41.88 18.71 7.37
Additional Paid-In Capital 169.20 150.93 86.24 399.12
Retained Earnings (Accumulated Deficit) -84.65 -43.50 -18.36 -382.87
Treasury Stock - Common
ESOP Debt Guarantee
Unrealized Gain (Loss)
Other Equity, Total 4.86 3.48
Total Equity 140.68 152.79 86.58 23.62
Total Liabilities & Shareholders Equity 155.93 186.06 109.64 38.72
Total Common Shares Outstanding 51.27 41.88 18.71 7.37
Total Preferred Shares Outstanding
Tangible Book Value per Share, Common Eq 0.76 1.27 -0.28 2.72
Cashflow
Net Income/Starting Line -42.63 -36.49 -13.08 -21.28
Depreciation/Depletion 0.62 0.77 0.34 0.68
Amortization 0.01 0.05 0.17 0.21
Deferred Taxes
Non-Cash Items 0.91 -0.38 -0.15 1.36
Changes in Working Capital -3.80 2.26 -8.53 -12.83
Cash from Operating Activities -44.89 -33.78 -21.26 -31.86
Capital Expenditure -0.90 -0.73 -0.01 -0.05
Other Investing Cash Flow Items, Total 9.37 -30.15 -12.71 15.15
Cash from Investing Activities 8.47 -30.88 -12.72 15.10
Financing Cash Flow Items
Total Cash Dividends Paid
Issuance (Retirement) of Stock, Net 11.06 87.18 15.00 0.00
Issuance (Retirement) of Debt, Net 0.00 14.79 -1.75 -1.46
Cash from Financing Activities 11.06 101.97 13.25 -1.46
Foreign Exchange Effects 0.27 0.29 0.46 0.22
Net Change in Cash -25.10 37.60 -20.27 -18.00
Cash Interest Paid 0.01 0.01 0.04 0.09
Cash Taxes Paid
Values are in EUR and expressed in million